Paul Badawi Sells 22,362 Shares of Sight Sciences (NASDAQ:SGHT) Stock

by · The Markets Daily

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) CEO Paul Badawi sold 22,362 shares of the stock in a transaction on Friday, January 16th. The stock was sold at an average price of $6.62, for a total value of $148,036.44. Following the completion of the transaction, the chief executive officer directly owned 6,025,840 shares of the company’s stock, valued at approximately $39,891,060.80. The trade was a 0.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Paul Badawi also recently made the following trade(s):

  • On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total transaction of $88,787.60.
  • On Friday, January 2nd, Paul Badawi sold 25,356 shares of Sight Sciences stock. The shares were sold at an average price of $7.43, for a total transaction of $188,395.08.

Sight Sciences Price Performance

Sight Sciences stock traded up $0.14 during trading hours on Wednesday, hitting $6.38. 326,019 shares of the company traded hands, compared to its average volume of 315,994. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $9.24. The firm has a market cap of $337.31 million, a P/E ratio of -7.09 and a beta of 2.42. The firm’s 50-day simple moving average is $7.81 and its two-hundred day simple moving average is $5.32. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.10. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The business had revenue of $19.91 million during the quarter, compared to analysts’ expectations of $17.74 million. As a group, analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

A number of large investors have recently made changes to their positions in the company. Americana Partners LLC purchased a new stake in shares of Sight Sciences in the 2nd quarter valued at approximately $3,568,000. Vanguard Group Inc. raised its stake in Sight Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock valued at $6,559,000 after purchasing an additional 102,609 shares during the period. B Group Inc. lifted its holdings in shares of Sight Sciences by 11.6% in the second quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after purchasing an additional 96,400 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in shares of Sight Sciences in the second quarter worth $328,000. Finally, Millennium Management LLC boosted its position in shares of Sight Sciences by 145.2% in the third quarter. Millennium Management LLC now owns 133,846 shares of the company’s stock worth $460,000 after buying an additional 79,265 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on SGHT shares. Lake Street Capital boosted their price objective on Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Citigroup lifted their target price on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a report on Monday, January 5th. Morgan Stanley raised their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, UBS Group lifted their price objective on shares of Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.30.

Get Our Latest Stock Report on SGHT

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

Featured Articles